Ruthenium-catalyzed  ||| S:0 E:20 ||| JJ
reductive  ||| S:20 E:30 ||| JJ
amination  ||| S:30 E:40 ||| NN
without  ||| S:40 E:48 ||| IN
an  ||| S:48 E:51 ||| DT
external  ||| S:51 E:60 ||| JJ
hydrogen  ||| S:60 E:69 ||| NN
source  ||| S:69 E:76 ||| NN
A  ||| S:76 E:78 ||| DT
ruthenium-catalyzed  ||| S:78 E:98 ||| JJ
reductive  ||| S:98 E:108 ||| JJ
amination  ||| S:108 E:118 ||| NN
without  ||| S:118 E:126 ||| IN
an  ||| S:126 E:129 ||| DT
external  ||| S:129 E:138 ||| JJ
hydrogen  ||| S:138 E:147 ||| NN
source  ||| S:147 E:154 ||| NN
has  ||| S:154 E:158 ||| VBZ
been  ||| S:158 E:163 ||| VBN
developed  ||| S:163 E:173 ||| VBN
using  ||| S:173 E:179 ||| VBG
carbon  ||| S:179 E:186 ||| NN
monoxide  ||| S:186 E:195 ||| NN
as  ||| S:195 E:198 ||| IN
the  ||| S:198 E:202 ||| DT
reductant  ||| S:202 E:212 ||| NN
and  ||| S:212 E:216 ||| CC
ruthenium ||| S:216 E:225 ||| NNS
( ||| S:225 E:226 ||| -LRB-
III ||| S:226 E:229 ||| NNP
)  ||| S:229 E:231 ||| -RRB-
chloride  ||| S:231 E:240 ||| NN
( ||| S:240 E:241 ||| -LRB-
0.008-2  ||| S:241 E:249 ||| CD
mol  ||| S:249 E:253 ||| JJ
% ||| S:253 E:254 ||| NN
)  ||| S:254 E:256 ||| -RRB-
as  ||| S:256 E:259 ||| IN
the  ||| S:259 E:263 ||| DT
catalyst ||| S:263 E:271 ||| NN
.  ||| S:271 E:273 ||| .
The  ||| S:273 E:277 ||| DT
method  ||| S:277 E:284 ||| NN
was  ||| S:284 E:288 ||| VBD
applied  ||| S:288 E:296 ||| VBN
to  ||| S:296 E:299 ||| TO
the  ||| S:299 E:303 ||| DT
synthesis  ||| S:303 E:313 ||| NN
of  ||| S:313 E:316 ||| IN
antianxiety  ||| S:316 E:328 ||| JJ
agent  ||| S:328 E:334 ||| NN
ladasten ||| S:334 E:342 ||| NN
.  ||| S:342 E:344 ||| .
